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ANALYSIS OF THE EFFECTS OF PHYSIOLOGICAL PERTURBATIONS ON 
THE BONE REMODELING PROCESS 
CYNTHIA XIE 
 
ABSTRACT 
The skeletal system is a dynamic organ that provides support, protection, aids in 
the production of all blood cells, and serves as a calcium ion reservoir. It is constantly 
undergoing a process called ‘remodeling’, which occurs through the actions of osteoclast 
and osteoblast cells. The former is responsible for breaking down bone whereas the latter 
secretes an organic matrix for bone synthesis.  
  Two experiments were conducted to analyze the effects of physiological 
perturbations on the bone remodeling process. Specifically, the impact of aging and 
selective serotonin re-uptake inhibitor administration coupled with lactation on bone 
morphology and composition were observed. The bony skeleton is not a stagnant organ, 
rather it undergoes functional, mechanical, and compositional changes throughout life. 
Thus, we wanted to determine the consequences age had on various bone parameters and 
found a decrease in bone volume fraction (BV/TV), trabecular number (Tb.N), cortical 
thickness (C.Th), and an increase in periosteal area, endosteal area, and cortical porosity 
(C.Po). In regards to pregnancy, post-partum depression is a common condition. As a 
result, many women utilize selective serotonin re-uptake inhibitors (SSRIs) to combat the 
negative symptoms associated with it. Serotonin is an important hormone involved in 
mood regulation and the mammary-derived form has a role in lactation. It induces the 
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production of parathyroid hormone-related protein, which is essential for regulating 
maternal calcium. Because the calcium source for milk production is derived from the 
maternal bone, we were interested in the impact peri-partum usage of SSRIs had on 
maternal bone mineral density. Additionally, we sought to understand the effect that 
circulating SSRIs had on the bone formation of pups. Analysis revealed age-related 
decreases in BV/TV, Tb.N, trabecular thickness (Tb.Th), C.Th and increases in trabecular 
spacing (Tb.Sp) and C.Po, with the effects being exacerbated in cohorts treated with a 
SSRI during lactation. We did not observe, however, any change in trabecular bone 
mineral density (Tb.BMD) or cortical bone mineral density (C.BMD) over time. In 
regards to the pups, we observed similar results to those of the dams in addition to a 
significant reduction in femur length. 
With the data obtained from the two projects, we hope that they bring awareness 
to potential consequences that physiological perturbations may have on the bone 
remodeling process. Both experiments have clinical correlations to humans. Further 
understanding the relationship between aging and bone may aid in developing 
methodologies to prevent age-related changes. On the other hand, analyzing the effects 
that SSRI usage has on maternal and child bone density may result in alternative methods 
to combat post-partum depression.   
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INTRODUCTION 
1.1 - An Overview of Bone Biology 
  The bony skeleton is a remarkable organ that serves not only a structural but also 
a reservoir function. It allows for locomotion, protects the vital organs, maintains acid-
base balance, and serves as a storehouse for essential minerals, such as calcium and 
phosphate. It is metabolically active and is continuously undergoing a process called 
remodeling, which is critical for maintaining its structural integrity. Bone is composed of 
collagen and calcium phosphate, which enable it to be strong yet flexible enough to 
withstand mechanical stress. 
  There are two types of bone categorized primarily on the basis of porosity. 
Cortical bone is dense and is found in the shafts of long bones or surrounds trabecular 
bone as a thin layer in the vertebrae. On the other hand, trabecular bone, also known as 
‘cancellous bone’, has a highly porous honeycomb-like structure. This type of bone is 
commonly found in the flat bones of the pelvis or at the ends of the long bones. The 
mature adult human skeleton consists of 80 percent cortical and 20 percent trabecular 
bone, by weight.2 Bone growth, or osteogenesis, occurs by means of two mechanisms: 
intramembranous and endochondral ossification. The former involves direct conversion 
of mesenchymal tissue into bone whereas the latter utilizes a hyaline cartilage model for 
bone formation.  
Intramembranous ossification is the characteristic way by which the flat bones of 
the skull and the clavicle are formed. It is a process that begins during fetal development 
and continues on until adolescence. First, mesenchymal cells derived from the neural 
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crest proliferate and condense. While some of these cells will develop into capillaries, 
others will differentiate into osteogenic cells and then osteoblasts, which come together 
to form a clustered region called the ossification center.3 The osteoblasts secrete an 
uncalcified matrix, called osteoid, that is able to bind calcium salts and hardens. Once 
this occurs, any osteoblasts trapped inside of the matrix become osteocytes. Osteoid that 
is secreted around the capillaries results in the formation of a trabecular matrix, whereas 
osteoblasts located on the surface of cancellous bone become the periosteum.3 The 
periosteum lies superficially to the majority of the bony structures and is composed of 
dense irregular connective tissue that is richly supplied with blood vessels. 
 
 
 
 
 
 
 
 
 
 
 
 Figure	1	–	Schematic	diagram	of	intramembranous	ossification.	Adapted	from	OpenStax	Anatomy	and	
Physiology,	2013.	Intramembranous	ossification	follows	four	steps.	(a)	Mesenchymal	cells	proliferate,	
differentiate,	and	group	into	clusters,	forming	ossification	centers.	(b)	Secreted	osteoid	traps	osteoblasts,	
which	then	become	osteocytes.	(c)	Formation	of	the	trabecular	matrix	and	periosteum.	(d)	Compact	bone	
develops	superficial	to	the	trabecular	bone	and	crowded	blood	vessels	condense	into	red	marrow.	
	3 
  In endochondral ossification, bones, particularly those at the base of the skull and 
the long bones, develop by replacing hyaline cartilage.4 Several weeks after conception, 
mesenchymal cells differentiate into chondrocytes, or cartilage producing cells, and form 
the perichondrium. It is composed of dense connective tissue and surrounds cartilage, 
except at joints. (Figure 2b) Vessels eventually penetrate the cartilage, providing 
abundant nutrients and initiating the transformation of the perichondrium into the bone-
forming periosteum. Osteoblasts form a collar of periosteal bone around the diaphyseal 
region, a component necessary to help the developing bone to retain its shape. The 
primary ossification center, located in the diaphysis of long bones, is formed during the 
first few months of fetal development (Figure 2c). Chondrocytes and cartilage continue to 
grow at the ends of the bone, increasing its length and ultimately forming the secondary 
ossification center (Figure 2d).  
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Figure	2	–	Diagram	of	endochondral	ossification.	Adapted	from	OpenStax	Anatomy	and	Physiology,	
2013.	Intramembranous	ossification	follows	five	steps.	(a)	Mesenchymal	cells	proliferate	and	differentiate	
into	chondrocytes.	(b)	Formation	of	the	hyaline	cartilage	model	and	the	perichondrium	for	the	bony	
skeleton.	(c)	Capillaries	penetrate	cartilage	and	the	perichondrium	turns	into	the	periosteum.	(d)	Cartilage	
and	chondrocytes	continue	to	grow	at	the	ends	of	the	bone.	(e)	Secondary	ossification	centers	develop.	(f)	
Cartilage	remains	at	epiphyseal	(growth)	plate	and	at	joint	surface	as	articular	cartilage.	
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  There are five types of cells found in bone: osteoblasts, bone lining cells, 
osteocytes, osteoprogenitor cells, and osteoclasts. Osteoblasts are cuboidal shaped cells 
that line the surfaces of bone and express a ligand called Receptor Activator of NF-κB 
Ligand (RANKL). They are regarded to be bone-forming cells as they synthesize and 
secrete organic bone matrix.5 Bone lining cells are “older” osteoblasts that line the 
surfaces of non-remodeling bone and are responsible for regulating the movement of 
minerals in and out of bone. Osteocytes are star-shaped cells that are connected to one 
another through cytoplasmic extensions. In fact, they are derived from osteoblasts that 
become trapped in the matrix they secrete and further differentiate into osteocytes. 
Ostocytes and their processes reside in regions called lacunae and canaliculi, 
respectively, and although they are not as metabolically active as osteoblasts they play an 
important role in the turnover of the bony matrix. Osteoprogenitor cells are capable of re-
differentiating into osteoblasts and are responsible for regulating the movement of 
mineral ions throughout the bone extracellular matrix.6 Osteoclasts (OCs) are multi-
nucleated cells that arise from the fusion of myeloid hematopoietic precursors formed in 
the bone marrow and are essential components of bone remodeling. Osteoclast precursors 
express receptors for Colony-stimulating factor-1 receptor (c-fms) and Receptor 
Activator of NF-κB (RANK). Upon interacting with RANKL found on osteoblasts, they 
can result in the formation of mature osteoclasts. 7 
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1.2 - The Role of the Osteoclast and It’s Importance in Bone Remodeling 
  The adult skeleton is constantly being remodeled, a mechanism involving the 
resorption of old or damaged bone on the same surface of where osteoblasts lay down 
new bone to replace that which was resorbed.8 Bone remodeling is a critical event in 
processes such as bone growth, fracture healing, exercise, and the maintenance of normal 
physiological levels of serum calcium.9 Remodeling continues throughout life so that the 
majority of the adult skeleton is replaced approximately every 10 years.10 
  Microscopically, bone is a vastly dynamic organ and remodeling involves the 
concerted action of the bone resorbing and forming cells. Bone remodeling takes place at 
any given region of the bone surface with the Basic Multicellular Unit (BMU), which is 
comprised of osteoclasts, osteoblasts, and osteocytes.11 Osteoblasts are derived from 
mesenchymal cells and components such as 1-alpha,25-dihydroxyvitamin D3, 
parathyroid hormone (PTH), prostaglandin E2 (PGE2), and interleukin-11 (IL-11) 
modulate their differentiation. 11,12 The fully differentiated osteoblast is characterized by 
the co-expression of alkaline phosphatase and type I collagen, both of which are 
important for synthesis of bone matrix and mineralization.13 Additionally, mature 
osteoblasts produce factors such as receptor activator of NF-κB ligand (RANKL), 
macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG). OPG is 
made by mature osteoblasts and acts as a soluble decoy receptor for RANKL; in fact, it 
inhibits osteoclastogenesis by blocking the RANK-RANKL interaction.11,12 As 
previously discussed, osteoclast precursors express c-Fms and RANK, receptors for M-
CSF and RANKL, respectively and in their presence, cause them to differentiate into 
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mature osteoclasts.   
 
 
 
 
 
 
 
 
Physiological Perturbations Can Disrupt the Bone Remodeling Process  
 
 
  
 
  
 
  When bone is to be digested, multinucleated osteoclasts attach tightly to the bone 
surface and forms a sealed compartment called the “sealing zone”.14 Within this region, 
the finger-like processes of the osteoclasts create the ruffled border, which is aimed at 
increasing the surface area of the cell (Figure 4). Osteoclasts release hydrogen ions and 
are pumped against a high concentration through vacuolar-ATPases that have 
accumulated in the ruffled border membrane. Chloride ions pass through a particular 
Figure 3 – Regulation of osteoclast differentiation and function by osteoblastic cells. Adapted from 
Takahasi, et al., BoneKEy Reports, 2014. Bone resorption-stimulating factors act on osteoblastic cells to 
induce the expression of RANKL as a membrane-associated factor. Osteoblastic cells constitutively produce 
m-CSF. Osteoclast precursors express receptors RANK and c-Fms and differentiate into osteoclasts in the 
presence of RAKNL and m-CSF. Osteoblast cells secrete OPG, which inhibits the RANK-RANKL interaction 
between osteoblast cells and osteoclast precursors. Multi-nucleated osteoclasts also express RANK and as 
a result, RANKL activates the bone-resorbing activity of the osteoclasts via the interaction with RANK. 
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chloride channel, namely CLCN7, subsequently allowing hydrochloric acid to be formed 
in the resorption lacunae to demineralize bone and expose the organic matrix.2,14 In 
addition, osteoclasts secrete proteolytic enzymes, such as cathepsin K (Cat-K) and acid, 
which hydrolyze and solubilize the inorganic components of bone, respectively.15  
 
 
 
 
 
 
 
 
 
 
 
 
1.3 - Physiological Perturbations Can Disrupt the Bone Remodeling Process 
  Bone growth and development are the result of complex interactions between 
genetics and environmental components. Yet, physiological perturbations may 
occasionally disrupt and negatively impact this balance. External factors such as exercise, 
aging, and lactation can all have a significant influence on bone mass and strength. Load 
bearing exercise increases bone mass, and exercise can improve coordination, balance 
Figure 4 – Osteoclasts resorbing bone. Adapted from Boyce et al., European Journal of Clinical 
Investigation, 2012. The ruffled border membranes (indicated with arrows) of multinucleated osteoclasts 
can be visualized as pale staining extensions of their cytoplasm adjacent to the bone surface, which they 
secrete proteolytic enzymes and hydrochloric acid to degrade bone. 
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and muscle strength, predictors of fall related fracture risk.16 Aging and lactation are both 
associated with lower bone mass, and in this work we further explore the effects of both 
on bone homeostasis in a rodent model.  
 
1.4 - An Overview of Aging 
  Aging is defined by the progressive loss of physiological integrity, impaired 
function, and increased vulnerability to death. This deterioration is the predominant risk 
factor for major human pathologies, including cancer, diabetes, cardiovascular disorders, 
and neurodegenerative diseases.17 There are numerous potential biological factors 
involved in the aging process, however it is imperative to note that aging is not a disease. 
Several major theories of aging, such as the free radical theory or telomere theory of 
aging, provide useful insight for understanding age-related physiological changes. The 
former states that all organisms live in an environment containing reactive oxygen 
species and consequently, the increasing age-related oxidative stress appears to be a 
consequence of the imbalance between free radical and anti-oxidant production.18 On the 
other hand, the telomere theory of aging claims that telomeres, which are DNA sequences 
located at the ends of eukaryotic chromosomes, are associated with cell mortality. With 
each round of cell division, telomere shortening occurs, which has been implicated as a 
potential molecular clock triggering cellular senescence, a decrease in proliferative 
capacity, and an increase in age-related pathologies.18  
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1.4.1 - Effects of Aging on the Skeletal System 
  As mentioned previously, bone has mechanical and protective roles, while serving 
as a site for calcium ion regulation. However, the properties of bone are not stagnant 
throughout life and rather their function deteriorates in most cases. Studies have shown 
that older individuals may have a 10-fold-increased 10-year fracture risk compared with 
younger individuals with the same bone mineral density (BMD).19 
As individuals grow older, changes in bone mechanical behavior causes greater 
tissue mineral content that results in stiffer but more brittle bonds. Similarly, alterations 
in the bones’ collagenous structure may contribute to increased brittleness, which not 
only impacts the organic matrix, but also the composition of the mineral component. 
Similarly, bone morphology appears to alter with development and aging in response to 
changes in load. As the shape of bone changes, its functional ability may be modified. As 
bone gets stiffer with age, its cross-sectional area decreases whereas the impact from the 
weight being supported increases. Consequently, this potentially results in bone 
deformation and fracture. 
 
1.4.2 – Aims and Hypothesis 
We hypothesize that because the skeletal system is consistently undergoing 
alterations with time, we would observe changes in bone parameters as the age of the 
cohorts increased. Specifically, we anticipated that there would be a decrease in BV/TV, 
Tb.N, Tb.Th, C.Th and an increase in Tb.Sp, C.Po, periosteal area, and endosteal area. 
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1.5 - An Overview of Lactation and Breastfeeding 
  The benefits a mothers’ own milk has significantly outweighs those of other 
nutritional sources. Because breastfeeding has been associated with enhanced cognitive 
development and lower incidence of allergies in infants, it is recommended to be the 
exclusive source of nourishment for at least six months and continued if desired mutually 
by the mother and infant.19 In addition to such, the production of prolactin and oxytocin 
facilitates decreased maternal stress and mother-infant bonding.20,21 In regards to the 
potential relationship between breastfeeding and behavioral outcomes during early 
childhood, researchers have discovered that it may protect against childhood internalizing 
disorders, such as depression and anxiety.21 
  Osteoporosis is a chronic metabolic bone disease that occurs in both men and 
women, but post-menopausal women are at a higher risk. Moreover, numerous studies 
have demonstrated the contributory effect pregnancy and lactation have on osteoporosis 
due to the significant amount of calcium transfered from the mother to the fetus or infant. 
During pregnancy, 2-3% of maternal calcium is transferred to the fetus primarily in the 
second and third trimester.22 However during the first six months of lactation, data show 
that women lose approximately 6-10% of bone.22 The calcium needed for breast milk 
production is provided through renal mechanisms and mobilized from the maternal 
skeleton.22,23 While it was initially believed that maternal bone mass recovers completely 
after weaning, recent epidemiological evidence challenges this notion. A study conducted 
in 2017 discovered that breastfeeding reduces cortical and trabecular bone density and 
these effects persist for at least 2.6 years after weaning.23 
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1.5.1 - Effects of Lactation and Peri-partum Anti-depressants on Bone Formation 
  Depression is a common illness among post-partum women; the prevalence of 
post-partum depression (PPD) has been estimated to be 10-15%.24,25 The effects are well 
documented and left untreated, can result in detrimental effects on the maternal-infant 
bond. Risk factors for PPD may include a history of depression prior or during the 
pregnancy, low socioeconomic status, or low levels of partner or external support. PPD 
can cause significant suffering in a new mother during a time when gratification should 
be at an all-time-high, according to societal expectations. They may feel as if their 
experiences are incongruous with their depressed state and overwhelmed with the tasks of 
caring for a new baby. Symptoms can be alleviated with the administration of SSRIs, 
such as fluoxetine (FLX). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Mechanism of action for selective serotonin re-uptake inhibitors. Adapted from Latimore et 
al., Journal of Perinatology, 2005. Normally, serotonin is released by vesicular transport into the synapse 
by the pre-synaptic nerve ending. Once serotonin has bound to receptor sites on the post-synaptic nerve 
ending, it is reabsorbed. However, SSRIs block the reabsorption of serotonin into the pre-synaptic nerve 
ending, consequently increasing its extracellular levels.   
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  Serotonin (5-HT) is a neurotransmitter found in the human body and is 
responsible for mood regulation. It is made from the essential amino acid tryptophan by 
the enzyme tryptophan hydroxylase 1 (TPH1), which catalyzes the rate limiting step of 
peripheral 5-HT synthesis. TPH1 is expresed at high levels in the bone, as well as pineal 
gland and gut. However, there is an additional form of the enzyme, TPH2, which is 
responsible for producing 5-HT in the brain. 5-HT is primarily found in the digestive 
system, however it can also be found throughout the central nervous system and blood 
platelets.26 Normally, serotonin is produced in the pre-synaptic nerve ending, released 
across the synaptic cleft in vesicles, and binds to receptors on the post-synaptic nerve 
ending. A signal is initiated and serotonin can either be taken back up by the neuron or 
broken down. Administration of SSRIs prevents the re-uptake process of serotonin, 
consequently increasing its exogenous concentration to increase signaling through its 
receptor (Figure 5). 
Mammary-derived 5-HT influences a variety of physiological pathways 
associated with lactation, primarily by inducing the production of parathyroid hormone-
related protein (PTHrP)27. Although parathyroid hormone (PTH) and PTHrP bind to the 
same receptor on osteoblasts, they are not entirely alike in their functions. Specifically, 
PTHrP fails to stimulate the enzymatic renal conversion of vitamin D to its active 
metabolite and consequently does not increase intestinal calcium absorption.28 
Additionally, PTHrP is essential for milk production and the maintenance of circulating 
maternal calcium.29 
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1.5.2 – Aims and Hypothesis 
  We hypothesize that because 5-HT regulates lactational calcium homeostasis, 
treatment of PPD with SSRIs during pregnancy and lactation would exacerbate bone loss. 
Specifically, we anticipate that both control and experimental groups would experience 
age-related decrease in bone, but that cohorts administered FLX would demonstrate a 
more significant loss. In addition, we used treatment with a TPH1 inhibitor to alter 5-HT 
levels. We compared the effects on maternal bone of treatment with either FLX or TPH1 
inhibitor during pregnancy and lactation to a sham treatment. 
  Furthermore, we sought to investigate the effects that peri-partum SSRI dam 
treatment had on the bones of the pups born to these mothers. We hypothesized that an 
alteration in maternal 5-HT could affect bone formation in the offspring. We analyzed the 
effects of treatments altering 5-HT levels on bone mass, femur length, endosteal area, 
periosteal area, and periosteal circumference. 
	15 
METHODS  
 
2.1 – Effects of Aging on the Skeletal System 
2.1.1 – Animals  
  For specific pathogen free (SPF) mice, SPF F1 hybrid CB6F1 mice at ages 3, 10, 
24 months were obtained from the National Institute of Aging Aged Rodent Colony. 
Femurs were collected between 7 and 14 days of arrival at the Brigham and Women’s 
Hospital vivarium. 
 
2.1.2 – Micro-computed tomography (µCT) 
  The structural properties of cancellous and cortical bone can be quantitatively 
evaluated using microCT. Cancellous, also known as trabecular, bone is typically 
analyzed below the growth plate, an area of bone abundant in trabeculae. Structural 
parameters that standardly reported include BV/TV and also properties of the trabecular 
network including Tb.Th, Tb.Sp, and Tb.N. Cortical parameters that are standardly 
reported include C.Po, C.Th, endosteal area, periosteal circumference, and periosteal 
area. For both trabecular and cortical bone, tissue bone mineral density or BMD can be 
calculated by comparison to reference phantoms of known hydroxyapatite density. 
  A Scanco Medical microCT 35 system with an isotropic voxel size of 7 µm was 
used to image the femur. Scans were conducted in 70% ethanol using an X-ray tube 
potential of 55 kVp, an X-ray intensity of 0.145 mF and an integration time of 600 ms. 
For the scans of the femur, a region beginning 0.3 mm proximal to the growth plate and 
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extending 1 mm proximally was selected for trabecular bone analysis. A second region 
0.6 mm in length and centered at the midpoint of the femur was used to calculate 
diaphyseal parameters. A semi-automated contouring approach was used to distinguish 
cortical from trabecular bone. The region of interest was thresholded using a global 
threshold that set the bone/marrow cut-off at 310 mg HA/cm3 for trabecular bone and 435 
mg HA/cm3 for cortical bone. 3-D microstructural properties of bone were calculated 
using software supplied by the manufacturer and reported according to consensus 
guidelines on rodent µCT. 
 
2.2.3 - Statistical Analysis 
  Statistical analysis was performed with GraphPad Prism version 7. Bone 
parameters were analyzed using a Kruskal-Wallis test with Dunn’s multiple comparison’s 
post-test. 
 
2.2 – Effects of Lactation and Peri-partum Anti-depressants on Bone Formation 
2.2.1 - Animals 
All experiments were performed under protocol number A01473 and approved by 
the Research Animal Care and Use Committee at the University of Wisconsin-Madison. 
Female C57BL/6 mice were individually housed in a controlled environmental facility 
for biological research in the Animal Science Department vivarium at the University of 
Wisconsin-Madison. Mice were either obtained through our mating colony or ordered 
from Jackson Laboratories when they were between 7-9 weeks of age ± 3 days (stock 
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000664, Jackson Laboratories, Bar Harbor, ME). Mice were maintained at a temperature 
of 25°C and humidity of 50%-60% on a 12-h light/dark cycle with free access to food 
and water. Beginning at 7 weeks of age, female mice were bred overnight with a male of 
approximately the same age. Wherever possible, littermates were utilized. Pregnancy was 
determined via visualization of the vaginal plug, at which time mice were individually 
housed. Dams were randomly assigned to two treatments: saline (n=16) or fluoxetine 
(Selective Serotonin Reuptake Inhibitor; n=14) injections. Beginning on the plug date, 
dams received daily intra-peritoneal injections of either sterile saline or 20 mg/kg 
bodyweight fluoxetine hydrochloride (Sigma-Aldrich F312) reconstituted in sterile 
saline. The final volume injected into each dam was 0.12 mL of either saline or 
fluoxetine reconstituted in saline. Injections occurred daily between 0070h and 0080h 
every day from the plug date through day 21 of lactation. On day 21 of lactation, pups 
were weaned from the dams. Following weaning, dams were aged to either 3 months 
(n=8 for saline, n=7 for fluoxetine) or 9 months (n=8 for saline, n=7 for fluoxetine) post-
weaning. Litters were not standardized.  
 
2.2.2 - Sample Collection  
 Milk yield was determined daily throughout lactation using the weigh-suckle-
weigh (WSW) method (2, 37). Pups were removed from their mothers at 0800h. After 
being separated for 4 hours, each litter was weighed and the number of pups was counted. 
The litters were then returned to the dam at 1200h and allowed to nurse for 45 minutes. 
Following 45 minutes of suckling, litters were weighed again in order to estimate milk 
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yield. Milk yields were standardized per pup by dividing the total milk yield for the litter 
by the number of pups in each litter on each day of lactation. Following a 7 to 8 hour fast 
during the day, blood was collected into Capillary Blood Collection tubes (Terumo T-
MG) from the maxillary vein on the plug date, d1 of lactation, d21 of lactation, and at the 
time of euthanasia at either 3 or 9 months post-weaning. Blood was allowed to sit at 4°C 
overnight in order to allow platelets to disrupt. Blood was spun down at 3,000 rpm for 20 
minutes in order to isolate serum. Serum was stored at -80°C until the time of assay.  
At either 3 or 9 months post-weaning, dams were euthanized via carbon dioxide 
inhalation followed by cervical dislocation. One femur was collected for microCT 
evaluation by allowing it to fix overnight in a histology cassette at 4°C in 4% 
paraformaldehyde and then placed into 70% ethanol until microCT analysis. The other 
femur was snap frozen in liquid nitrogen for RNA analysis and stored at -80°C.  
 
2.2.3 - Micro-computed tomography 
  Bones were shipped in 70% ethanol to the laboratory of Dr. Julia Charles at 
Brigham and Women’s Hospital in Boston, MA for microCT analysis. A Scanco Medical 
microCT 35 system with an isotropic voxel size of 7 µm was used to image the femur. 
Scans were conducted in 70% ethanol using an X-ray tube potential of 55 kVp, an X-ray 
intensity of 0.145 mF and an integration time of 600 ms. For the scans of the femur, a 
region beginning 0.28 mm proximal to the growth plate and extending 1.05 mm 
proximally was selected for trabecular bone analysis. A second region 0.6 mm in length 
and centered at the midpoint of the femur was used to calculate diaphyseal parameters. A 
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semi-automated contouring approach was used to distinguish cortical from trabecular 
bone. The region of interest was thresholded using a global threshold that set the 
bone/marrow cut-off at 600 mg HA/cm3 for trabecular bone and 786 mg HA/cm3 for 
cortical bone. 3-D microstructural properties of bone, including bone volume fraction 
(BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N.), trabecular spacing 
(Tb.Sp.), trabecular bone mineral density (Tb.BMD), cortical thickness (C.Th), cortical 
porosity (C.Po), and cortical bone mineral density (C.BMD), were calculated using 
software supplied by the manufacturer and reported according to consensus guidelines on 
rodent µCT.  
 
2.2.4 - Statistical Analysis 
  Statistical analysis was performed with GraphPad Prism version 7. Bone 
parameters were analyzed using a Mann-Whitney for between group analysis and a 
Kruskal-Wallis test with Dunn’s multiple comparisons post-test for within group 
analysis. 
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RESULTS 
 
3.1 – Effects of Aging on the Skeletal System  
3.1.1 – Effect of Aging on Trabecular Bone Parameters in Male SPF Mice 
  It was anticipated that there would be a decrease in BV/TV as mice were aged 
over time. There was a significant decrease in BV/TV with age (p < 0.0001 Kruskal-
Wallis test). Subsequent inter-group comparative analysis revealed that although there 
was a significant difference in BV/TV between 3 versus 24 months of age (p < 0.0001), 
there was not one between 3 versus 10 months and 10 versus 24 months of age (p = 
0.0719 and p = 0.4384, respectively) (Figure 6A). 
  Similarly, it was hypothesized that there would be a decline in Tb.N as the age of 
the cohorts rose. There was a significant decrease in Tb.N with age within the male SPF 
cohorts (p < 0.0001). Subsequent examination of whether there was a difference in Tb.N 
between two aging time points demonstrated there was a significant difference between 3 
versus 24 months of age (p < 0.0001) but not one between 3 versus 10 and 10 versus 24 
months of age (p = 0.0558 and p = 0.5756, respectively) (Figure 6B). 
    In regards to Tb.Th, statistical analysis showed that there was a significant 
decrease with age (p = 0.0368). However, a Dunn’s multiple comparisons test established 
that between group differences were only significant when comparing 3 versus 10 months 
of age (p = 0.0453), while 3 versus 24 and 10 versus 24 months of age were not 
significant (p > 0.9999 and p = 0.0575, respectively) (Figure 6C). 
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3.1.2 – Effect of Aging on Cortical Bone Parameters in Male SPF Mice 
   C.Th also decreased significantly with age in male mice (p = 0.0117, Kruskal 
Wallis). However, further analysis of between group differences using Dunn’s multiple 
comparisons test revealed that C.Th differed significantly only between 3 versus 24 
months of age (p = 0.0166) , and there was not a significant difference between 3 versus 
10 and 10 versus 24 months of age (p > 0.9999 and p = 0.1022, respectively) (Figure 7A). 
  Periosteal area increased significantly with age (p < 0.0001). Further analysis 
revealed that there was a significant increase in periosteal area when 3 and 24 months of 
age were compared (p < 0.0001), but not a significant difference between 3 versus 10 and 
10 versus 24 months of age (p = 0.6289 and p = 0.1145, respectively) (Figure 7B). 
  Consistent with the decline in cortical thickness, endosteal area increased with age 
in parallel with increases in periosteal area (p < 0.0001). The difference in endosteal area 
was significant between 3 and 24 months of age groups (p < 0.0001), while endosteal 
area changes were not significant for 3 versus 10 and 10 versus 24 months of age (p > 
Figure	6	–	Graphs	of	trabecular	bone	parameters	in	male	SPF	mice.	Tb.	BV/TV,	Tb.N,	and	Tb.Th	are	
graphed	with	each	point	representing	one	mouse.	Significance	was	determined	Kruskal-Wallis	test	with	
Dunn’s	multiple	comparisons	test.	
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0.1833 and p = 0.2609, respectively) (Figure 7C). 
  Statistical evaluation of C.Po revealed that there was a significant difference in 
such between 3, 10, and 24 months of age (p = 0.0281). However, subsequent 
comparisons between two aging time points showed that there was a significant 
difference in C.Po between 3 and 24 months of age (p = 0.0426), but not during 3 versus 
10 or 10 versus 24 months of age (p > 0.9999 and 0.1484, respectively) (Figure 7D).	 
 
 
 
 
 
 
 
 
3.1.3 – Effect of Aging on Trabecular Bone Parameters in Female SPF Mice 
  BV/TV decreased significantly with age (p < 0.0001). Further analysis showed 
that there was a significant difference between 3 versus 10, 3 versus 24, and 10 versus 24 
months in age. There was in fact a significant difference between all age time points, 
which were p = 0.0487, p < 0.0001, and p = 0.0079, respectively (Figure 8A).  
  Tb.N decreased significantly with age (p < 0.0001). Additional analysis 
demonstrated that there was a significant difference between 3 versus 10, 3 versus 24, 
and 10 versus 24 months in age, where the p-values were 0.0215,  < 0.0001, and 0.0124, 
Figure	7	–	Graphs	of	cortical	bone	parameters	in	male	SPF	mice.	C.Th,	periosteal	area,	endosteal	area,	and	
C.Po	are	graphed	with	each	point	representing	one	mouse.	Significance	was	determined	Kruskal-Wallis	test	
with	Dunn’s	multiple	comparisons	test.	
B	
	23 
respectively (Figure 8B). 
  Tb.Th did not differ significantly with age (p = 0.0712). Similarly, a Dunn’s 
multiple comparisons test presented no significant difference between between 3 versus 
10, 3 versus 24, and 10 versus 24 months in age, where the p-values were 0.6062,  > 
0.9999, and 0.0658, respectively (Figure 8C). 
   
 
 
 
 
 
 
 
3.1.4 – Effect of Aging on Trabecular Bone Parameters in Female SPF Mice 
  C.Th increased significantly with age (p < 0.0001). Additional assessment showed 
that there was a there was a significant difference in C.Th between 3 versus 10 and 3 
versus 24 months of age (p = 0.0005 and p = 0.0003, respectively), but there was not one 
at 10 versus 24 months of age (p > 0.9999) (Figure 9A).  
  Periosteal area significantly increased with age (p < 0.0001). Further analysis 
demonstrated that when 3 versus 10, 3 versus 24, and 10 versus 24 months of age were 
compared against one another, they differed significantly (p = 0.0348, p < 0.0001, and p 
= 0.0116, respectively) (Figure 9B). 
Figure	8	–	Graphs	of	trabecular	bone	parameters	in	female	SPF	mice.	Tb.	BV/TV,	Tb.N,	and	Tb.Th	are	
graphed	with	each	point	representing	one	mouse.	Significance	was	determined	Kruskal-Wallis	test	with	
Dunn’s	multiple	comparisons	test.	
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  Endosteal area significantly increased with age as well (p < 0.0001). Follow-up 
evaluation was performed to determine whether there was a significant difference in 
endosteal area when comparing two aging time points to each other. The data indicated 
that there there was a significant difference between 3 versus 24 and 10 versus 24 months 
(p < 0.0001 and p = 0.0023, respectively) but not one between 3 versus 10 months of age 
(p = 0.5765) (Figure 9C). 
  C.Po decreased significantly with age (p < 0.0001). Additional analysis 
comparing C.Po between two aging time points revealed that there was a significant 
difference between 3 versus 10 and 3 versus 4 months of age (p = 0.0006 and p = 0.0003, 
respectively). However, there was not a significant difference in C.Po when 10 and 24 
months of age were assessed together (p > 0.9999) (Figure 9D).  
 
 
 
 
 
 
 
 
 
 
 
 
  To conclude, prior experimentation conducted by others demonstrated that female 
B6 mice, the standard laboratory strain, lose trabecular and cortical bone with age. 
However, we extended this work to evaluate the degree of bone loss in hybrid mice and 
Figure	9	–	Graphs	of	cortical	bone	parameters	in	female	SPF	mice.	C.Th,	periosteal	area,	endosteal	area,	
and	C.Po	are	graphed	with	each	point	representing	one	mouse.	Significance	was	determined	Kruskal-Wallis	
test	with	Dunn’s	multiple	comparisons	test.	
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in males. Our primary finding is that male mice, under standard SPF conditions, 
experience a loss of trabecular and cortical bone with age and that the mid-shaft cortical 
porosity increases. Bone loss with age in females is similar, with the exception that an 
increase in mid-shaft cortical porosity was not observed. 
 
3.2 – Effects of Lactation and Peri-partum Anti-depressants on Bone Formation 
 
3.2.1 – Effect of Fluoxetine on Bone Formation in Comparison to Control Group 
 
 
  When comparing the control and experimental groups at the three time points, 
there was not a significant difference between them at 6 or 9 months post-lactation (p = 
0.2222 and p = 0.3798, respectively), except for at 3 months post-lactation (p = 0.0379) 
(Figure 10A). As previously discussed, 5-HT regulates calcium homeostasis through 
PTHrP and drives bone resorption during lactation. We evaluated several bone 
parameters, specifically bone volume fraction (BV/TV), trabecular number (Tb.N), 
trabecular thickness (Tb.Th), and trabecular spacing (Tb.Sp). In regards to BV/TV, we 
anticipated that both the control and FLX treated groups would experience a decrease 
over time, but the experimental group would exhibit a lower BV/TV than the former in 
the months post-lactation.  
 In regards to Tb.N, we expected that both the control and FLX treated groups 
would experience an age-related decrease in Tb.N, except that the loss would be 
exacerbated in the treatment group. However when comparing the control and 
experimental group to one another throughout the months post-lactation, there was no 
significant difference between the control versus FLX at either  3 (p = 0.0973),  6 (p = 
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0.2222), or 9 months post-lactation (p = 0.152) (Figure 10B). 
  For Tb.Sp, we hypothesized that for the control and experimental groups that both 
would experience an increase in Tb.Sp within the months post-lactation but the latter 
would demonstrate a more drastic rise in Tb.Sp. Rather, there was no apparent significant 
difference between the control and fluoxetine treated groups at any of the time points. 
Statistical analysis revealed that the p-values for when 3, 6, and 9 months post-lactation 
FLX treated groups were compared to their corresponding control groups were p = 
0.0973, p = 0.2222, and p = 0.0541 (Figure 10C).  
  Lastly for Tb.Th, it was anticipated that the control and FLX treated groups would 
exhibit an age-related decrease in Tb.Th. Additionally, it was expected that the group that 
received FLX administration would demonstrate a more drastic decrease in Tb.Th over 
time. Nevertheless, there was no significant difference in Tb.Th when the control group 
was compared to the experimental group at 3, 6, and 9 months post-lactation (p = 0.1282, 
p = 0.1274, and p = 0.6943, respectively) (Figure 10D). 
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  With-in group differences for the aforementioned bone parameters were analyzed. 
It was anticipated that BV/TV, Tb.N, and Tb.Th would decrease whereas Tb.Sp would 
increase in the control groups, yet these parameters would be exacerbated in the 
experimental group. In regards to control group BV/TV values, the Kruskal-Wallis test 
indicated that there was in fact a significant decrease in BV/TV with time post-lactation 
within the control treated groups (p = 0.0068). Thus, similar to the hybrid virgin females 
examined in the last section, BV/TV decreases with age from 3 months post-lactation to 9 
months post-lactation. Dunn’s multiple comparisons test revealed that there was a 
significant difference between 3 months versus 6 months post-lactation (p = 0.0139) and 
6 months versus 9 months post-lactation (p = 0.0046) in the control group for BV/TV 
Figure	10	–	Graphs	of	various	bone	parameters	in	control	and	FLX	treated	mice.	BV/TV,	Tb.N,	Tb.Sp,	and	
Tb.Th	are	graphed	with	each	point	representing	one	mouse.	Between	group	significance	was	determined	
by	Mann-Whitney	test.	
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(Figure 11A). 
  For the group that received FLX administration, there was also a significant 
decline in BV/TV with time after lactation (p = 0.0001). As a result, it is evident that 
there is a decrease in BV/TV with age in the FLX treated group. Dunn’s multiple 
comparisons test demonstrated that although there was no significant difference between 
3 months versus 6 months post-lactation, there was a significant difference at 6 months 
versus 9 months post-lactation (p = 0.0047) (Figure 11B).  
 
 
 
 
 
 
 
  Tb.N within the control treatment group decreased with time after lactation (p = 
0.0031). Additionally, a subsequent comparison test indicated that there was a significant 
difference between 3 versus 6 months post-lactation (p = 0.0309) and 6 versus 9 months 
post-lactation (p = 0.0019) (Figure 12A). Tb.N also decreased with time after lactaion in 
the FLX treated group (p = 0.0002). According to Dunn’s multiple comparison’s test, 
there was no significant difference between 3 versus 6 months post-lactation. However, 
there was a significant difference between 6 months versus 9 months post-lactation (p = 
0.0018). Consequently, it can be stated that there is a progression towards a decrease in 
Figure	11	–	With-in	group	differences	of	BV/TV	in	control	and	FLX	treated	groups.	Each	point	represents	
one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
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Tb.N for both the control FLX treated group with age (Figure 12). 
 
 
 
 
 
   
 
    Tb.Sp increased significantly with time post-lactation for both the control treated 
group (p = 0.0031, Fig 12A) and the FLX treated group (p = 0.0002, Fig 13B). 
Additionally, further analysis with a Dunn’s multiple comparison’s test demonstrated that 
there was a significant difference between 3 versus 6 months post-lactation (p = 0.0309) 
and 6 versus 9 months post-lactation (p = 0.0019). In the FLX group,  Dunn’s multiple 
comparison’s test demonstrated that there was no significant difference between 3 versus 
6 months post-lactation, yet there was one between 6 versus 9 months post-lactation (p = 
0.0018) As a result, it can be concluded that Tb.Sp increased with age in both the control 
and FLX treated groups (Figure 13). 
 
 
 
 
Figure	12	–	With-in	group	differences	of	Tb.N	in	control	and	FLX	treated	groups.	Each	point	represents	
one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
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  The bone parameter Tb.Th did not change signficiantly with time post-lactation in 
the control group, nor were there signficant between-time point differences (Figure 14A). 
Similarly, Tb.Th did not change with time post-lactation in cohorts treated with FLX. 
Similarly there were no significant difference between 3 versus 6 months post-lactation 
and 6 versus 9 months post-lactation for Tb.Th for the FLX treated group (Figure 14B). 
 
 
 
 
 
 
   
  When analyzing C.Po, we anticipated that both the control and experimental 
groups would demonstrate an age-related increase in C.Po at each time point post-
Figure	14	–	With-in	group	differences	of	Tb.Th	in	control	and	FLX	treated	groups.	Each	point	represents	
one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
Figure	13	–	With-in	group	differences	of	Tb.Sp	in	control	and	FLX	treated	groups.	Each	point	represents	
one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
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lactation but that the fluoxetine treated group would exhibit a greater rise in C.Po. In 
contrast to our expectations, there was no observed difference in significance between the 
control and FLX treated groups at 3, 6, and 9 months post-lactation (p = 0.8929, p = 
0.2844, and p > 0.9999, respectively) (Figure 15A). 
 Concerning C.Th, we expected that both the control and experimental groups 
would display a decrease in C.Th at 3, 6, and 9 months post-lactation. Additionally, we 
believed that the FLX treated group would experience a larger loss of C.Th as the months 
post-lactation continued. However when comparing the control and experimental groups 
to each other at 3, 6, and 9 months post-lactation, the data at each time point did not 
significantly differ from each other (p = 0.8845, p = 0.5967, and p = 0.7114, respectively) 
(Figure 15B). 
 
 
 
 
 
 
 
 
 
 
      
 
  It was hypothesized that the control and FLX treated groups would experience an 
increase in C.Po with age, however the changes in C.Po would be more drastic in the 
latter. In analyzing the within group differences for C.Po, a Kruskal-Wallis test 
demonstrated a significant difference in the control group for C.Po (p = 0.0187), thus it 
Figure	15	–	Graph	of	cortical	bone	parameters	in	control	and	FLX	treated	mice.	C.Po	and	C.Th	are	graphed	
with	each	point	representing	one	mouse.	Significance	was	determined	by	Mann-Whitney	non-parametric	
test.	
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could be stated that the control group demonstrated a trend towards a decrease in C.Po 
with age. However, a Dunn’s multiple comparison’s test revealed that there was a 
significant difference between 3 versus 6 months post-lactation (p = 0.0129) but none for 
6 versus 9 months post-lactation (p = 0.0913) (Figure 16A). 
   Likewise, analysis of C.Po for the FLX treated cohorts illustrated that there was a 
difference in significance within the group between the various time points (p = 0.0359). 
Further investigation showed that there was neither a significant difference between 3 
versus 6 months post-lactation (p = 0.1851) nor between 6 versus 9 months post-lactation 
(p = 0.4972). Consequently, it can be concluded that within the FLX treated group, there 
is a progression towards an increase in C.Po with age (Figure 16B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 We expected to observe a decline in C.Th in both the control and experimental 
groups, yet the treatment group would demonstrate a larger decrease in C.Th. There was 
a significant difference within the control group (p = 0.0144). As a result, it can be 
gathered that the control group exhibited a trend towards a decrease in C.Th over time. 
Further investigation with a Dunn’s multiple comparison’s test demonstrated that 
Figure	16	–	With-in	group	differences	of	C.Po	in	control	and	FLX	treated	groups.	Each	point	represents	
one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
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although there was a significant difference in C.Th between 3 versus 6 months post-
lactation (p = 0.0092) there was not one between 6 versus 9 months post-lactation (p = 
0.0909) (Figure 17A). 
    The group administered FLX did exhibit a significant difference within the group 
(p = 0.0226). On the other hand, there was no significant differene between 3 versus 6 
months post-lactation (p = 0.1604) but the difference in C.Th between 6 versus 9 months 
post-lactation was significant (p = 0.0205). As a result, it can be stated that there is a 
progression towards a decrease in C.Th for the FLX treated group within the months 
post-lactation (Figure 17B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   In addition to the aforementioned bone parameters, we decided to evaluate 
whether there were age and FLX related changes in Tb.BMD and C.BMD in the cohorts. 
With respect to Tb.BMD, we observed that there was not a difference in regards to bone 
mineral density in each age group when the control and experimental groups were 
compared to one another (p = 0.8048, p = 0.0549, and p = 0.5358, respectively) (Figure 
18A). Similarly, there was no apparent difference in C.BMD between the control and 
Figure	17	–	With-in	group	differences	of	C.Th	in	control	and	FLX	treated	groups.	Each	point	represents	
one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
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FLX treated groups at 3 and 9 months post-lactation (p = 0.6943 and p = 0.4634, 
respectively) (Figure 18B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  To further understand the impact of age-related changes within groups, the effects 
on Tb.BMD and C.BMD within the control and FLX treated cohorts were analyzed at 
specific time points post-lactation. We did not observe any significant difference in 
Tb.BMD within either group or time point. Significance values for 3 versus 6 and 6 
versus 9 months post-lactation in the control group were p = 0.3698 and p = 0.9179, 
correspondingly and similarly, those for the FLX administered samples were both p > 
0.9999. Additionally, there was no difference in signifiance in Tb.BMD in the control 
and experimental groups when the three time points were compared together (p = 0.096 
and p = 0.9526, respectively) (Figure 19).  
 
 
 
 
 
 
 
 
Figure	18	–	Graphs	of	Tb.BMD	and	C.BMD	in	control	and	FLX	treated	groups.	Each	point	represents	one	
mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
	
Figure	18	–	Graphs	of	Tb.BMD	and	C.BMD	in	control	and	FLX	treated	mice.	Tb.BMD	and	C.BMD	are	
graphed	with	each	point	representing	one	mouse.	Between	group	significance	was	determined	by	Mann-
Whitney	test.	
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  Likewise, we did not note a significant difference in C.BMD in the control or 
FLX treated groups when any of two time points were evaluated against each other. The 
relevant significance values for 3 versus 6 and 6 versus 9 months post-lactation in the 
control cohorts were p = 0.0542 and p = 0.3249, respectively, whereas those for the FLX 
administered cohorts were p = 0.6374 and p > 0.9999, respetively (Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	20	–	With-in	group	differences	of	C.BMD	in	control	and	FLX	treated	groups.	Each	point	represents	
one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
	
Figure	19	–	With-in	group	differences	of	Tb.BMD	in	control	and	FLX	treated	groups.	Each	point	represents	
one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	multiple	
comparisons	test.	
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3.2.2 – Effect of TPH1 Inhibitor on Bone Formation in Comparison to Control Group 
 
  As mentioned prior, tryptophan hydroxylase (TPH) is the enzyme critical for 
catalyzing the production of serotonin from tryptophan. While there are two forms of 
TPH, namely TPH1 and TPH2, the effects of the former on various bone parameters were 
observed here. 
  We anticipated that the control and TPH1 inhibitor treated groups would 
experience a decrease in BV/TV with age post-lactation, but that the changes in these 
parameters in the TPH1 inhibitor treated group would not be as drastic as those 
experienced by the control treated group. Statistical analysis revealed that there was not a 
significant difference between the control and TPH1 treated cohorts when they were 
compared to one another at 3, 6, and 9 months post-lactation (p = 0.1282, p = 0.083, and 
p = 0.2909, respectively) (Figure 21A).  
  Likewise, we hypothesized that both the control and TPH1 inhibitor administered 
cohorts would showcase a decline in Tb.N within the months post-lactation. However, we 
expected that the loss of Tb.N displayed by the TPH1 inhibitor treated cohorts would not 
be as great as those of the control group. Evaluation of whether there were any significant 
differences between the control and TPH1 inhibitor treated groups at each of the aging 
time points revealed that there was not a significant difference at 3, 6, and 9 months post-
lactation (p = 0.0650, p = 0.3829 and p = 0.3282, respectively) (Figure 21B). 
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   Considering within group differences for BV/TV for the TPH1 inhibitor treated 
cohort, there was no significant difference when the three time points were compared 
together (p = 0.1547). Furthermore, a Dunn’s multiple comparisons test demonstrated 
that there was no significant difference between 3 versus 6 months and 6 versus 9 months 
post-lactation in BV/TV for the TPH1 inhibitor treated groups (p > 0.9999 and p = 
0.1490, respectively) (Figure 22A). 
  In regards to Tb.N, there was a significant decrease with time post-lactation with 
a TPH1 inhibitor (p = 0.001). Furthermore, Dunn’s multiple comparison’s test revealed 
that there was a significant difference between 3 versus 6 months post-lactation (p = 
Figure	21	–	Graphs	of	various	bone	parameters	in	control	and	TPH1	inhibitor	treated	mice.	BV/TV,	Tb.N,	
Tb.Sp,	and	Tb.Th	are	graphed	with	each	point	representing	one	mouse.	Between	group	significance	was	
determined	by	Mann-Whitney	test.	
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0.0048) and 6 versus 9 monts post-lactation (p = 0.0004) (Figure 22B) 
  Tb.Sp increased signficiantly with time post-lactation in the TPH1 treament group 
(p = 0.001). Additional analysis with a Dunn’s multiple comparison’s test indicated that 
although there was no significant difference between 3 versus 6 months post-lactation (p 
= 0.0848), there was one between 6 months versus 9 months post-lactation in regards to 
Tb.Sp (p = 0.0004) (Figure 22C). 
  We also observed an time post-lactation-related significant increase in Tb.Th 
within the cohorts that were administered a TPH1 inhibitor (p = 0.0208). Supplementary 
analysis with a Dunn’s multiple comparison’s test presented no significant difference 
between 3 versus 6 months post-lactation (p = 0.0603) however there was one between 6 
months versus 9 months post-lactation (p = 0.017) (Figure 22D). 
 
 
 
 
 
 
 
 
 
 
   
Figure	22	–	With-in	group	differences	of	various	bone	parameters	in	control	and	TPH1	inhibitor	treated	
groups.	Each	point	represents	one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	
test	with	Dunn’s	multiple	comparisons	test.	
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  We hypothesized that the age-related increase in C.Po and decrease in C.Th 
would be partially ameliorated in the TPH1 inhibitor treated group. However, our data 
revealed that there was no difference in significance in regards to C.Po when the control 
and TPH1 inhibitor cohorts were evaluted against one another at 3, 6, and 9 months post-
lactation (p = 0.4825, p = 0.0650, p = 0.7209, respectively) (Figure 23A). Similarly, C.Th 
did not differe signficantly between the control and TPH1 inhibitor cohorts at 3 and 9 
months post-lactation (p = 0.4550 and p = 0.8999, respectively). However, there was a 
small but statistically signficant difference in C.Th between the control and TPH1 
inhibitor treated groups at 6 months post-lactation (p = 0.0157) (Figure 23B). 
 
 
 
 
 
    
 
  Neither C.Po and C.Th differed with time-post lactation for either the TPH1 
inhibitor nor the control treated group.  Within the TPH1 inhibito treated group, C.Po was 
unchanged with age/time post-lactation (p = 0.7014) as was C. Th (p = 0.3102), nor were 
there signficant differences between individual time points (Fig. 24).   
 
 
Figure	23	–	Graphs	of	C.Po	and	C.Th	in	control	and	TPH1	inhibitor	treated	mice.	Each	point	represents	
one	mouse.	Between	group	significance	was	determined	by	Mann-Whitney	test.	
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  Within group analysis of the effects of a TPH1 inhibitor on Tb.BMD and C.BMD 
were evaluated. Looking at the three post-lactation time points together, there was not a 
significant difference in Tb.BMD between the three time points (p = 0.0644). 
Additionally, the data revealed that there was in fact no significant difference when 3 and 
6 months post-lactaiton were compared to one another in regards to Tb.BMD (p = 
0.3234), however there was a difference in significance when 6 and 9 months post-
lactation were observed together (p = 0.0428) (Figure 25A). 
  Similarly, the TPH1 inibitor treated group did not demonstrate any difference in 
C.BMD with time post-lactation (p = 0.3315). Further analysis regarding 3 versus 6 
months and 6 versus 9 months post-lactation demonstrated that their was no apparent 
significant difference in C.BMD (p > 0.9999 and p = 0.3028, respectively) (Figure 25B). 
 
 
 
Figure	24	–	With-in	group	differences	of	C.Po	and	C.Th	in	TPH1	inhibitor	treated	groups.	Each	point	
represents	one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	test	with	Dunn’s	
multiple	comparisons	test.	
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3.3.3 – Effect of Fluoxetine on Bone Formation in Pups 
  In addition to analyzing the effects of SSRI treatment on maternal bone, we 
sought to observe whether peri-partum administration of FLX or TPH1 inhibitor 
impacted the bone of offspring whose mothers were exposed to treatment . In addition to 
evaluating the bone parameters that were discussed previously in the maternal lactation 
section, we analyzed endosteal area, periosteal circumference, periosteal area, and femur 
length.  
  BV/TV was significantly different between the three groups (p = 0.0019). 
Subsequently, each of the categorizations were compared to the others, revealing that 
while there was not a significant difference between the control versus TPH1 inhibitor 
nor FLX versus TPH1 inhibitor treated cohorts (p = 0.1086 and p > 0.9999, respectively), 
there was a significant difference in BV/TV in the pups when the control group was 
compared to that of the FLX treated samples (p = 0.0013) (Figure 26A). 
Figure	25	–	With-in	group	differences	of	Tb.BMD	and	C.BMD	in	control	and	TPH1	inhibitor	treated	
groups.	Each	point	represents	one	mouse.	With-in	group	differences	were	determined	by	a	Kruskal-Wallis	
test	with	Dunn’s	multiple	comparisons	test.	
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   Similarly, Tb.N differed significantly among the three treatment cohorts (p = 
0.0017). In between-group comparisons demonstrated that Tb.N between the control and 
FLX administered samples differed sign?ficantly (p = 0.0011) while there was no 
significant difference between the control and TPH1 inhibitor or FLX and TPH1 inhibitor 
comparisons (p = 0.1268 and p = 0.9257, respectively) (Figure 26B). 
  Similarly, we observed a significant difference in Tb.Sp between the control, 
FLX, and TPH1 inhibitor treated samples (p = 0.0017). Further analysis revealed that 
there was a significant difference in Tb.Sp between the control and FLX groups (p = 
0.0011) whereas there was a significant difference when the control and TPH1 inhibitor 
or FLX and TPH1 inhibitor cohorts were compared to one another (p = 0.1268 and p = 
0.9257, respectively) (Figure 26C). 
  Concerning Tb.Th, there was a significant difference between the three groups (p 
= 0.0012). However when we evaluated each of the groups to one another, there was not 
a significant difference in Tb.Th between the control versus TPH1 inhibitor treatment and 
FLX versus TPH1 inhibitor cohorts (p = 0.3123 and p = 0.3731, respectively). On the 
other hand, there was a difference in Tb.Th when the control and FLX administered 
samples were analyzed (p = 0.0008) (Figure 26D). 
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  Given the differences in the trabecular bone of the pups from the FLX treatment 
group, we were interested in determining if there were differences in the cortical bone. 
Examination of C.Po revealed that the control, FLX, and TPH1 inhibitor treated cohorts 
differed significantly from one another (p = 0.0002). On the other hand, supplementary 
analysis indicated that when two groups were compared to each other, only the control 
and FLX administered samples differed significantly in C.Po (p = 0.0001) whereas the 
control versus TPH1 inhibitor and FLX versus TPH1 inhibitor samples did not (p = 
0.1509 and 0.4326, respectively) (Figure 27A). 
  Assessment of C.Th showed that the control, FLX, and TPH1 inhibitor 
Figure	26	–	Graphs	of	various	bone	parameters	in	control,	FLX,	and	TPH1	inhibitor	treated	mice.	BV/TV,	
Tb.N,	Tb.Sp,	and	Tb.Th	are	graphed	with	each	point	representing	one	pup.	Significance	was	determined	by	
a	Kruskal-Wallis	test	with	Dunn’s	multiple	comparisons	test.	
	
	44 
administered groups differed significantly in terms of C.Th (p = 0.0367). However, 
subsequent comparisons demonstrated that while the control versus TPH1 inhibitor and 
FLX versus TPH1 inhibitor samples did not differ significantly from each other (p > 
0.9999 and p = 0.2284), the control and FLX treated cohorts significantly differed from 
each other with regards to C.Th (p = 0.0459) (Figure 27 B). 						
 			 For Tb.BMD, we observed that the control, FLX, and TPH1 inhibitor 
administered cohorts did not differ significantly from one another in terms of Tb.BMD (p 
= 0.1922), nor were there significant between group differences. (Figure 28A). 
   Measurement of C. BMD showed that the groups differed significantly (p = 
0.009). However, pairwise comparison of the groups showed that only the control versus 
FLX cohorts displayed a significant difference in regards to C.BMD (p = 0.0140) 
whereas those in the control versus TPH1 inhibitor or FLX versus TPH1 inhibitor cohorts 
did not display any difference (p = 0.0603 and p > 0.9999, respectively) (Figure 28B). 	
Figure	27	–	Graphs	of	C.Po	and	C.Th	in	control,	FLX,	and	TPH1	inhibitor	treated	mice.	C.Po	and	C.Th	are	
graphed	with	each	point	representing	one	pup.	Significance	was	determined	by	a	Kruskal-Wallis	test	with	
Dunn’s	multiple	comparisons	test.	
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  Lastly, we sought to determine the effects of peri-partum FLX, and TPH1 
administration in the dams on the endosteal area, periosteal circumference, periosteal 
area, and femur length of the pup bones. There was not a significant difference between 
the groups for endosteal area, periosteal circumference, or periosteal area (p = 0.6315, p 
= 0.5657, and p = 0.7188, respectively). Additional pair-wise comparisons between 
groups similarly showed no difference in any of these parameters (p > 0.9999) (Figure 
29A-C). 
  In contrast, femur length differed significantly amongst the three groups (p = 
0.0032). Furthermore when comparing each of the groups to one another, there was a 
significant difference between the control and FLX cohorts as well between the FLX and 
TPH1 inhibitor treated groups with respect to femur length (p = 0.0056 and p = 0.0375, 
respectively). When the control and TPH1 groups were compared, there was not a 
significant difference in femur length (p > 0.9999) (Figure 29D). 
    
Figure	28	–	Graphs	of	Tb.BMD	and	C.BMD	in	control,	FLX,	and	TPH1	inhibitor	treated	mice.	Tb.BMD	and	
C.BMD	are	graphed	with	each	point	representing	one	pup.	Significance	was	determined	by	a	Kruskal-Wallis	
test	with	Dunn’s	multiple	comparisons	test.	
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 			 To summarize, we wanted to understand the effects peri-partum SSRI treatment 
of dams had on the bones of pups. Our primary findings were that maternal treatment 
with FLX significantly decreased pup femur length, there was no observed difference in 
periosteal or endosteal area, a decrease in BV/TV, Tb.N, and Tb.Th, an increase in Tb.Sp, 
and no effects on cortical parameters nor on either cortical or trabecular BMD. 	
Figure	29	–	Graphs	of	endosteal	area,	periosteal	area,	periosteal	circumference,	and	femur	length	in	
control,	FLX,	and	TPH1	inhibitor	treated	mice.	Endosteal	area,	periosteal	area,	periosteal	circumference,	
and	femur	length	are	graphed	with	each	point	representing	one	pup.	Significance	was	determined	by	a	
Kruskal-Wallis	test	with	Dunn’s	multiple	comparisons	test.	
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DISCUSSION 
 
4.1 – The Effects of Aging and Peri-partum Anti-depressants on the Skeletal System 
  The goal of this study was to understand the effects of physiological perturbations 
on the bone remodeling process. Specifically two physiological processes were 
examined: aging and lactation. 
  We believed that in terms of the aging, the cohorts regardless of sex would 
demonstrate age-related chances in cortical and trabecular bone parameters. Our data 
supported our hypothesis in that we observed a decrease in Tb. BV/TV and Tb.N, an 
increase in periosteum area and endosteal area, and similar changes in Tb.Th over time. 
However, we noticed juxtaposing results for C.Po and C.Th. We anticipated that the 
aging cohorts would exhibit a decrease in C.Th and an increase in C.Po with age, as seen 
in the male aging samples but not in the females. In this study, the cortical parameters for 
the femurs were evaluated based on the diaphyseal region. However, an investigation 
conducted by Piemontese et al. in 2017 revealed that the increased cortical porosity with 
age was most prominent in the metaphyseal regions.30 In future studies, we will re-
evaluate the cortical parameters in the metaphyseal rather than at the diaphyseal region 
to determine whether the changes in C.Th and C.Po match those of what we would 
expect. 
  In regards to lactation, we were interested in understanding the effects that peri-
partum SSRI treatment had on maternal bone density. Our findings revealed that there 
was a significant decrease in BV/TV, Tb.N, and C.Th. Additionally, we observed a  
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significant increase in Tb.Sp and C.Po. However, we did not see any change in Tb.Th or 
on either cortical or trabecular BMD. 
  Additionally, we sought to assess the effects that peri-partum SSRI treatment of 
dams had on the bones of the pups. We found that maternal treatment with FLX peri-
partum significantly decreased pup femur length when compared to either the control or  
TPH1 inhibitor treated cohorts. No differences were observed in periosteal or endosteal 
area, suggesting that there was no effect on radial bone growth. In addition, FLX 
treatment led to lower trabecular BV/TV in the pups, with corresponding changes in 
Tb.N, Tb.Th and Tb.S.  However, no effects on cortical parameters nor on either cortical 
or trabecular BMD were observed. 
  There are several facets of these experiements that could potentially be improved 
upon for further experimentation. Firstly, the specific drug that was selected for this 
particular experiment was Fluoxetine, which is the most widely prescribed anti-
depressant on the market. However, drugs may bind to “off-target” locations and elict 
unintended effects. Thus, it may be beneficial to conduct a follow-up study with another 
SSRI to determine whether the results from the experiment can be replicated and a class-
effect of SSRI is seen. Secondly, while our data did support several of our hypotheses, 
greater significance in regards to statistical analysis could be obtained if we increased the 
number of animals per treatment group and time point. Thirdly, all samples were 
administered a defined dose of the specific treatment they were receiving. For further 
experimentation, it may prove to be beneficial to utilize higher or lower dosages to 
determine whether a dose responsive effect on the bone parameters is seen. In terms of 
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the pups, the number of litters per dam should be standardized if a follow-up study were 
to be conducted. For the dams that gave birth to larger numbers of pups, the pups would 
be receiving far less nutrition than those in smaller litters. Furthermore, it is possible that 
the dams that had larger litters received FLX treatment, thus litter standardization would 
be advantageous as it would enable us to decipher whether the effects of FLX are truly 
due to the treatment or to less nutrition.	
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